Belite Bio Submits Marketing Authorization Applications for Tinlarebant
Belite Bio says it submitted marketing authorization applications for tinlarebant via the Access Consortium pathway to treat Stargardt disease type 1.
Belite Bio says it submitted marketing authorization applications for tinlarebant via the Access Consortium pathway to treat Stargardt disease type 1.